Sloan Sheldon bought SYRE
April 1, 2026 · Form 4 insider transaction
Sloan Sheldon bought 7,958 shares of Spyre Therapeutics, Inc. at $21.66 per share, a transaction worth $172.4K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
7,958
Price
$21.66
Total value
$172.4K
InsiderSloan Sheldon
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateApril 1, 2026
Filing dateApril 3, 2026
Shares owned after7,958
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.